Plazas, J GallegoArias-Martinez, ALecumberri, AMartínez de Castro, ECustodio, ACano, J MHernandez, RMontes, A FMacias, IPieras-Lopez, ADiez, MVisa, LTocino, R VLago, N MartínezLimón, M LGil, MPimentel, PMangas, MGranja, MCarnicero, A MPérez, C HernándezGonzalez, L GJimenez-Fonseca, PCarmona-Bayonas, A2023-05-032023-05-032022-06-14http://hdl.handle.net/10668/22218Recommendations for research articles include the use of the term sex when reporting biological factors and gender for identities or psychosocial or cultural factors. There is an increasing awareness of incorporating the effect of sex and gender on cancer outcomes. Thus, these types of analyses for advanced gastroesophageal adenocarcinoma are relevant. Patients with advanced gastroesophageal adenocarcinoma from the Spanish AGAMENON-SEOM registry treated with first-line combination chemotherapy were selected. Epidemiology, characteristics of the disease, treatment selection, and results were examined according to sex. This analysis included 3274 advanced gastroesophageal adenocarcinoma patients treated with combination chemotherapy between 2008 and 2021: 2313 (70.7%) men and 961 (29.3%) women. Tumors in females were more frequently HER2-negative (67.8% versus 60.8%; P This sex analysis of patients with advanced gastroesophageal adenocarcinoma from the AGAMENON-SEOM registry receiving first-line polychemotherapy found no differences in survival. Although women had worse prognostic histopathology, metastatic disease pattern, and greater toxicity, treatment allocation and compliance were equivalent.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/gastroesophageal cancergendersexsurvivaltoxicityAdenocarcinomaAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleProgression-Free SurvivalRegistriesStomach Neoplasmsresearch article35714478open access10.1016/j.esmoop.2022.1005142059-7029PMC9271495http://www.esmoopen.com/article/S205970292200134X/pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271495/pdf